Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
Trump’s 60 Minutes interview touched on AI safety, threat to arrest an AI exec
- a day ago
Did the midterms kill MAGA?
- 6 hours ago
The UV-tracking Gem made me rethink how sunlight affects my health, not just my appearance
- 8 hours ago
Instagram’s AI age detection is expanding globally
- a day ago
Soul Glo’s Diaspora Problems is a hardcore record like no other
- 8 hours ago
Who will take care of us when we get old?
- 21 hours ago
Epic Games Launcher is coming to SteamOS
- 8 hours ago
NYT Cooking’s AI assistant saved my weeknight chicken, but almost ruined my cake
- 8 hours ago
Are you abandoning the fight if you move from a red state to a blue one?
- 21 hours ago
Hegseth’s “maximum lethality” comes back to haunt him
- 6 hours ago
Pakistan calls for dialogue, implementation of peace deal in South Sudan
- a day ago
Iran will not allow enriched nuclear material to leave the country, security chief says
- 21 hours ago
